All In Biotech

Drug Trial Radar · NCT06983743

A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

A Phase 1/2 Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 5, 2025

Primary completion

May 1, 2028

Study completion Dec 1, 2028

Sponsor

Lead sponsor
Erasca, Inc.Industry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.

Conditions

  • Metastatic Solid Tumors

Interventions

  • ERAS-0015Drug

    ERAS-0015 Administered orally

  • ERAS-0015 in combinationDrug

    ERAS-0015 Administered orally and in combination with either KEYTRUDA® (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 21
  2. Maximum tolerated dose (MTD)Time frame: Study Day 1 up to Day 21
  3. Recommended dose for expansion (RDE)Time frame: Study Day 1 up to Day 21
  4. Adverse EventsTime frame: Study Day 1 up to Day 21
  5. Plasma concentration (Cmax)Time frame: Study Day 1 up to 65
  6. Time to achieve Cmax (Tmax)Time frame: Study Day 1 up to 65
  7. Area under the curveTime frame: Study Day 1 up to 65
  8. Half-lifeTime frame: Study Day 1 up to 65

Locations

14 sites in 3 countries. Site status is shown where the registry gives one.

  • Providence Medical Group

    Santa Rosa, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Florida Cancer Specalists

    Sarasota, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Massachusetts General Hospital (MG)

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Texas at Tyler

    Tyler, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • The Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Recruiting

  • Seoul St. Mary's Hospital Clinical Trial Center

    Seoul, South Korea · Recruiting

  • Inje University Haeundae Paik Hospital Clinical Trial Center

    Haeundae, Busan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.